Kapil Mayawala
About Kapil Mayawala
Kapil Mayawala serves as the Vice President of Clinical Pharmacology and Clinical Development at Generate Biomedicines, where he has worked since 2022. He has extensive experience in oncology drug development, having held senior roles at notable companies such as Merck and Pfizer.
Work at Generate Biomedicines
Kapil Mayawala serves as the Vice President of Clinical Pharmacology and Clinical Development at Generate Biomedicines. He has held this position since 2022, contributing to the company's efforts in advancing oncology drug development. His role involves overseeing clinical pharmacology strategies and ensuring the successful progression of clinical programs.
Education and Expertise
Kapil Mayawala studied at the Indian Institute of Technology (IIT), Kanpur, and furthered his education at the University of Delaware and the University of Chicago. He possesses deep expertise in biologics, particularly within the oncology research and development sector. His academic background supports his extensive knowledge and skills in clinical pharmacology.
Background
Kapil Mayawala has a diverse professional background in the pharmaceutical industry. He has worked at several major companies, including Merck, Pfizer, and Novartis, where he held various roles focused on oncology and biologics. His career spans multiple positions, including Senior Director at Merck and Senior Principal Scientist at Pfizer, showcasing his extensive experience in drug development.
Achievements
Throughout his career, Kapil Mayawala has been involved in strategic decision-making regarding pipeline strategy and in-licensing/acquisition at senior executive levels. He has experience in regulatory filing processes for oncology drug development and has contributed to all stages of oncology drug development, from discovery through clinical development.